Daily Endocrinology Research Analysis
Three high-impact endocrinology papers span mechanistic discovery and practice-changing guidance: (1) α cell FATP2 inhibition triggers GLP-1 secretion to enhance β-cell insulin release, unveiling a novel diabetes target; (2) FGFR2 signaling is essential for adrenal zona glomerulosa identity, and its blockade suppresses β-catenin-driven hyperplasia and aldosterone production; (3) AACE’s 2025 obesity/ABCD algorithm advances complication-centric, person-centered care with prioritized pharmacotherap
Summary
Three high-impact endocrinology papers span mechanistic discovery and practice-changing guidance: (1) α cell FATP2 inhibition triggers GLP-1 secretion to enhance β-cell insulin release, unveiling a novel diabetes target; (2) FGFR2 signaling is essential for adrenal zona glomerulosa identity, and its blockade suppresses β-catenin-driven hyperplasia and aldosterone production; (3) AACE’s 2025 obesity/ABCD algorithm advances complication-centric, person-centered care with prioritized pharmacotherapy hierarchies.
Research Themes
- Islet alpha–beta cell crosstalk via GLP-1 and metabolic target discovery
- Adrenal morphogenesis signaling (FGFR2–β-catenin) and aldosterone regulation
- Obesity (ABCD) guideline evolution with complication-centric pharmacotherapy
Selected Articles
1. Fatty acid transport protein 2 inhibition enhances glucose tolerance through α cell-mediated GLP-1 secretion.
Using db/db mice, α-cell lines, and human islets, the authors show that FATP2 is selectively expressed in α cells and constrains GLP-1 secretion. Genetic deletion or pharmacologic inhibition of FATP2 increases α-cell GLP-1, enhancing paracrine insulin release and lowering glucose, independent of gut enteroendocrine GLP-1.
Impact: This reveals a previously unrecognized α-cell FATP2–GLP-1 axis controlling β-cell insulin secretion, providing a mechanistically distinct diabetes target from GLP-1RA/DPP-4 pathways.
Clinical Implications: Selective FATP2 inhibitors could enhance endogenous intra-islet GLP-1 and insulin secretion, complementing incretin-based drugs and benefiting patients with T2D, pending safety and efficacy in humans.
Key Findings
- Islet FATP2 expression is restricted to α cells and functionally active.
- FATP2 knockout in db/db mice lowers glucose via sustained insulin secretion with reduced basal glucagon and gluconeogenesis.
- Small-molecule FATP2 inhibitors increase GLP-1 secretion in αTC1-6 cells and human islets, with exendin(9-39)-sensitive insulin release.
- Enteroendocrine GLP-1 contribution was excluded by similar oral vs. i.p. glucose responses and lack of intestinal FATP2–GLP-1 colocalization.
Methodological Strengths
- Convergent evidence from genetic knockout mice, α-cell line, and human islets.
- Use of pharmacologic inhibition and receptor antagonism (exendin[9-39]) to prove mechanism.
Limitations
- Preclinical study without in-human efficacy or safety data for FATP2 inhibitors.
- Quantitative sample sizes and long-term metabolic outcomes are not detailed in the abstract.
Future Directions: Develop selective, safe FATP2 inhibitors; test efficacy and durability in human T2D; map lipid species controlling α-cell GLP-1 secretion; evaluate synergy with GLP-1RA/SGLT2i.
Type 2 diabetes affects more than 38 million people in the United States, and a major complication is kidney disease. During the analysis of lipotoxicity in diabetic kidney disease, global fatty acid transport protein 2 (FATP2) gene deletion was noted to markedly reduce plasma glucose in db/db mice due to sustained insulin secretion. To identify the mechanism, we observed that islet FATP2 expression was restricted to α cells and that α cell FATP2 was functional. Basal glucagon and alanine-stimulated gluconeogen
2. Abrogation of FGFR signaling blocks β-catenin-induced adrenocortical hyperplasia and aldosterone production.
FGFR2 maintains zona glomerulosa identity and function. Conditional Fgfr2 deletion blocks β-catenin-driven zG hyperplasia and reduces aldosterone. Short-term pan-FGFR inhibitors suppress aldosterone in wild-type and β-catenin gain-of-function mice, nominating FGFR signaling as a therapeutic target in aldosterone excess.
Impact: Identifies an actionable signaling axis controlling aldosterone production and β-catenin-driven adrenocortical hyperplasia, with both genetic and pharmacologic validation.
Clinical Implications: FGFR inhibitors, some already in clinical use for other indications, could be repurposed or optimized for hyperaldosteronism and adrenal hyperplasia, warranting translational studies.
Key Findings
- zG-specific Fgfr2 deletion disrupts zG identity, proliferation, and induces transdifferentiation toward zF.
- Fgfr2-cKO abrogates β-catenin-induced zG hyperplasia and lowers aldosterone levels.
- Short-term pan-FGFR inhibitor treatment suppresses aldosterone in both WT and β-catenin gain-of-function mice.
Methodological Strengths
- Cell type–specific genetic deletion with adult inducible models to separate development from maintenance.
- Pharmacologic corroboration with pan-FGFR inhibitors across genotypes.
Limitations
- Preclinical mouse-focused study; human adrenal tissue validation and clinical dosing/safety are not yet established.
- Short-term inhibitor exposure; long-term effects on electrolyte balance and blood pressure were not detailed in the abstract.
Future Directions: Validate FGFR2 signaling in human adrenal tissues and primary aldosteronism subtypes; assess selective FGFR inhibitor efficacy/safety; explore combination with mineralocorticoid receptor antagonists.
Fibroblast growth factor receptors (FGFRs) are tyrosine kinase receptors critical for organogenesis and tissue maintenance, including in the adrenal gland. Here we delineate the role of FGFR2 in the morphogenesis, maintenance, and function of the adrenal cortex with a focus on the zona glomerulosa (zG). zG-specific Fgfr2 deletion (Fgfr2-cKO) resulted in impaired zG cell identity, proliferation, and transdifferentiation into zona fasciculata (zF) cells during postnatal development. In adult mice, induced deleti
3. American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease - 2025 Update.
The AACE 2025 consensus reframes obesity as ABCD, emphasizing complication-centric, person-centered chronic care, individualized therapeutic intensity, and prioritized pharmacotherapy hierarchies. It outlines screening, diagnosis (anthropometric and clinical), treatment goals, behavioral therapy, medication selection (including cost-sensitive step therapy), and FDA-approved anti-obesity agents.
Impact: As a widely used clinical algorithm, this update can harmonize and upgrade obesity care, reduce bias and stigma, and optimize medication selection across diverse settings.
Clinical Implications: Promotes complication-centric assessment beyond BMI, structured pharmacotherapy hierarchies (including GLP-1/GIP agonists), and cost-sensitive step therapy, enabling pragmatic, equitable obesity care and shared decision-making.
Key Findings
- Centers obesity management on complication burden and person-centered goals, not BMI alone.
- Provides hierarchies of preferred and lower-cost pharmacotherapies with individualized selection.
- Defines screening/diagnosis pathways (anthropometric and clinical), therapeutic targets, and follow-up strategies.
Methodological Strengths
- Multidisciplinary expert task force aligning with related AACE guidance.
- Algorithmic, visual decision support to aid implementation at point of care.
Limitations
- Consensus guidance lacks randomized comparative effectiveness data within the document.
- Excludes surgical/procedural therapies and pediatric care, limiting scope.
Future Directions: Prospective evaluations of algorithm-guided care on outcomes, costs, and equity; integration with digital decision support and pragmatic trials across diverse populations.
OBJECTIVE: This 2025 consensus statement provides evidence-based visual guidance in graphic algorithms and a summary of evidence to assist health care professionals and adults with obesity and adiposity-based chronic disease (ABCD) in shared decision making to improve care and achieve health goals. METHODS: AACE selected a task force of medical experts to update the 2016 AACE algorithm for the medical care of patients with obesity and align this algorithm update with related AACE clinical guidance. Details on surge